A Ohgami1, T Tsuda, T Osaki, T Mitsudomi, Y Morimoto, T Higashi, K Yasumoto. 1. Institute of Industrial Ecological Sciences and Department of Surgery II, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan. gamisan@med.uoeh-u.ac.jp
Abstract
BACKGROUND: MUC1 is a membrane-bound mucin with an extensively O-glycosylated core protein and is developmentally regulated and aberrantly expressed by carcinomas. A high level of MUC1 mucin expression and secretion is associated with high metastatic potential and a poor prognosis. We studied the expression of MUC1 messenger ribonucleic acid (mRNA) in stage I lung adenocarcinoma by reverse transcriptase-polymerase chain reaction and examined its correlation with early recurrence. METHODS: The expression of MUC1 mRNA, in surgical specimens from 33 patients with stage I lung adenocarcinoma was determined by reverse transcriptase-polymerase chain reaction. The MUC1 and beta-actin sequences were subsequently coamplified to analyze the semiquantitative determination by polymerase chain reaction. The ratio of MUC1 to beta-actin product was used for further analysis. RESULTS: An analysis of the disease-free survival (median follow-up, 33.4 months) revealed that a high expression of MUC1 was associated with early recurrence (p = 0.0191). Six of the 33 patients had recurrence within 2 years after operation. The recurrence sites suggested hematogenic metastasis. CONCLUSIONS: Our results indicate that MUC1 mRNA level may be useful as a marker of early recurrence in stage I lung adenocarcinoma.
BACKGROUND:MUC1 is a membrane-bound mucin with an extensively O-glycosylated core protein and is developmentally regulated and aberrantly expressed by carcinomas. A high level of MUC1mucin expression and secretion is associated with high metastatic potential and a poor prognosis. We studied the expression of MUC1 messenger ribonucleic acid (mRNA) in stage I lung adenocarcinoma by reverse transcriptase-polymerase chain reaction and examined its correlation with early recurrence. METHODS: The expression of MUC1 mRNA, in surgical specimens from 33 patients with stage I lung adenocarcinoma was determined by reverse transcriptase-polymerase chain reaction. The MUC1 and beta-actin sequences were subsequently coamplified to analyze the semiquantitative determination by polymerase chain reaction. The ratio of MUC1 to beta-actin product was used for further analysis. RESULTS: An analysis of the disease-free survival (median follow-up, 33.4 months) revealed that a high expression of MUC1 was associated with early recurrence (p = 0.0191). Six of the 33 patients had recurrence within 2 years after operation. The recurrence sites suggested hematogenic metastasis. CONCLUSIONS: Our results indicate that MUC1 mRNA level may be useful as a marker of early recurrence in stage I lung adenocarcinoma.
Authors: Dhara M MacDermed; Nikolai N Khodarev; Sean P Pitroda; Darrin C Edwards; Charles A Pelizzari; Lei Huang; Donald W Kufe; Ralph R Weichselbaum Journal: BMC Med Genomics Date: 2010-05-06 Impact factor: 3.063